Evidence map›Paper›PMID 32655495›Full record

ReviewFrontiers in endocrinology2020

Modulation of the Inflammatory Response and Bone Healing.

Masahiro Maruyama, Claire Rhee, Takeshi Utsunomiya, Ning Zhang, Masaya Ueno, Zhenyu Yao, Stuart B Goodman

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 279 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
279citing papers in PubMed, 2 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

279 citing papers in PubMed, 2 syntheses or guidelines pooled it, 473 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. ABCB5⁺ mesenchymal stem cells enable high-ratio cellular augmentation of bone grafts without loss of osteogenic function.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026
    Article
  8. Article
  9. Applications of DNA Hydrogels in Osteoporotic Bone Defects.Journal of functional biomaterials · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Temporal immunomodulation of CD4Science advances · 2026
    Article
  18. Review
  19. Article
  20. Article

219 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masahiro MaruyamaDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Claire RheeDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Takeshi UtsunomiyaDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Ning ZhangDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Masaya UenoDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Zhenyu YaoDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Stuart B GoodmanDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, United States.
Stanford University · US

Funding

Wear Particle Disease and NF-kappa B SignalingR01AR063717 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2012 to 2021
$3.5M
Chemokine Directed Cell Trafficking during Continuous Infusion of Wear ParticlesR01AR055650 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2007 to 2016
$3.3M
Tissue Engineering Approaches for Improved Treatment of Early Stage Osteonecrosis of the HipR01AR072613 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B, YANG, YUNZHI · 2018 to 2022
$2.2M
Customized MSCs to Enhance Healing of Bone DefectsR01AR073145 · NIAMS · STANFORD UNIVERSITY · PI GOODMAN, STUART B · 2018 to 2021
$1.4M
NIAMS NIH HHS R01 AR055650NIAMS NIH HHS R01 AR063717NIAMS NIH HHS R01 AR072613NIAMS NIH HHS R01 AR073145
6 · The paper itself

Abstract

The optimal treatment for complex fractures and large bone defects is an important unsolved issue in orthopedics and related specialties. Approximately 5-10% of fractures fail to heal and develop non-unions. Bone healing can be characterized by three partially overlapping phases: the inflammatory phase, the repair phase, and the remodeling phase. Eventual healing is highly dependent on the initial inflammatory phase, which is affected by both the local and systemic responses to the injurious stimulus. Furthermore, immune cells and mesenchymal stromal cells (MSCs) participate in critical inter-cellular communication or crosstalk to modulate bone healing. Deficiencies in this inter-cellular exchange, inhibition of the natural processes of acute inflammation, and its resolution, or chronic inflammation due to a persistent adverse stimulus can lead to impaired fracture healing. Thus, an initial and optimal transient stage of acute inflammation is one of the key factors for successful, robust bone healing. Recent studies demonstrated the therapeutic potential of immunomodulation for bone healing by the preconditioning of MSCs to empower their immunosuppressive properties. Preconditioned MSCs (also known as "primed/ licensed/ activated" MSCs) are cultured first with pro-inflammatory cytokines (e.g., TNFα and IL17A) or exposed to hypoxic conditions to mimic the inflammatory environment prior to their intended application. Another approach of immunomodulation for bone healing is the resolution of inflammation with anti-inflammatory cytokines such as IL4, IL10, and IL13. In this review, we summarize the principles of inflammation and bone healing and provide an update on cellular interactions and immunomodulation for optimal bone healing.

Indexed as

Fracture HealingAnimalsBone and BonesFractures, BoneHumansInflammationInflammation MediatorsMesenchymal Stem CellsInflammation Mediatorsanti-inflammatory cytokinesbone healingimmunomodulationinflammationmesenchymal stromal cellpreconditioningpro-inflammatory cytokines

Identifiers

PMID32655495
PMCPMC7325942
OpenAlexW3034944990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.